| INTRODUC TI ON
Next-generation sequencing (NGS) was first used to analyze the biology of cancers. 1 It has since been rapidly implemented in clinical oncology to guide therapy. 2, 3 EGFR, ALK, ROS1 and BRAF mutations account for approximately 30% and 60% of adenocarcinomas in the United States and Japan, respectively, and treatment targeting these gene alterations has been approved globally. 4, 5 In addition, expression levels of PD-L1 and tumor mutation burden have been shown to predict response to immune checkpoint inhibitors. [6] [7] [8] As the number of genes to analyze has increased, the need to simultaneously analyze multiple genes has grown.
Targeted sequencing is considered superior to whole genome or whole exome sequencing in the clinical setting because of higher accuracy and lower costs. the ones likely to benefit most from NGS. It is unknown whether DNA and RNA of adequate quality can be extracted from these samples to allow high-quality sequencing.
The aim of this study was to compare CTNB, EBUS-TBNA and TBB with surgical resection and to determine whether samples obtained through these methods are feasible for clinically targeted NGS.
| MATERIAL S AND ME THODS
One hundred and seven consecutive samples from 67 patients were Details of DNA/RNA extraction and targeted sequencing have been described elsewhere. 11 In brief, DNA was extracted from whole blood using a Maxwell RSC Blood DNA Kit (Promega), and DNA and RNA were extracted from FFPE samples using a GeneRead DNA FFPE Kit (Qiagen) and an RNeasy FFPE Kit (Qiagen), respectively. DNA yield was quantified by quantitative PCR and DNA quality was determined by the ddCq method using FFPE DNA QC Assay v2 (Thermo Fisher Scientific); this compares the amplification efficiency of short and long amplicons, which reflects the amount of DNA that has been degraded. 13 RNA yield was quantified by Qubit4 (Thermo Fisher Scientific) and DV200
was measured using the 4200 TapeStation System (Agilent quality and sequencing were set so that the average depth would be 500× or higher. NGS analysis from RNA was considered successful if 100× coverage was achieved in more than 70% of housekeeping genes; cutoffs for RNA yield, quality and sequencing were set to achieve this goal.
As all analyzed data did not show normal distributions, KruskalWallis one-way analysis of variance on ranks was used to compare multiple groups. Pairwise multiple comparisons were performed using Dunn's test. We confirmed that one-way analysis of variance with Tukey's post-hoc analysis gave similar results. Statistical analyses were performed using SigmaPlot 12.3 (Systat Software) and R (version 3.5.0).
| RE SULTS
A median of 2, 4 and 7 biopsies were taken from CTNB, EBUS-TBNA and TBB, respectively. The diameter of biopsy samples taken from
CTNB is approximately 1 mm; the median sum of the lengths was 3 mm. The median diameter of the samples taken through EBUS-TBNA and TBB was 2 mm. Two samples were biopsied after EGFR tyrosine kinase inhibitor and one was biopsied after chemotherapy.
DNA and RNA were extracted from samples within 1 year after biopsy in 33 of 37 samples (89%).
We first analyzed the quantity and quality of DNA and RNA.
DNA yield from the 3 biopsy methods was similar and less than the yield obtained from resected samples ( Figure 1A and Table 1 ,
Quality of DNA, as measured by ddCq, was similar across all 4 methods ( Figure 1B ). RNA yield from the 3 biopsy methods was also similar and less than the yield obtained from resected samples ( Figure 1C , P < 0.001). DV200 was similar across all 4 methods ( Figure 1D ). In short, the yield was lower with biopsy We next analyzed the quality of sequencing. Total read number, number of unique reads and percentage of reads on target were all similar for DNA analysis ( Table 2 ). The average depth was similar across all 4 methods (Figure 2A ). RNA analysis also gave a similar number of total reads across the 4 methods, and the percentage of housekeeping genes with coverage of over 100× was also similar ( Figure 2B ).
To determine the rates of adequate DNA and NGS quality, cutoffs for DNA yield were set at 50 ng, ddCq at 8.0, total reads at 40 million, unique reads at 12 million, percentage on target at 30%, and depth at 200×. DNA yield was higher than 50 ng in 80% of CTNB samples, 100%
of EBUS-TBNA samples, 82% of TBB samples and 99% of resected samples ( TA B L E 2 Percentage of samples considered satisfactory for each lung tumor biopsy method F I G U R E 2 Quality control measures of targeted next generation sequencing for each biopsy method. A, Average depth. B, Estimated tumor content of 11 TBB samples (73%) and 63 of 66 resected samples (95%).
Seven samples had RNA yields below the detection limit. Of 7 samples, 4 also had DV200 of <50% and all 4 samples were not suitable for NGS analysis, while 2 of 3 samples with RNA yield below the detection limit but DV200 over 50% had successful NGS runs.
| D ISCUSS I ON
Precision medicine has been adopted in clinical oncology to maximize survival of patients with advanced cancer. NGS helps to characterize each cancer and is rapidly being implemented to guide therapy.
However, surgical resection is too invasive in patients with advanced cancer, and small biopsy samples, which are a few millimeters in size, are taken from the tumor to reach a pathological diagnosis. We have shown that small biopsy samples mostly yield adequate quality DNA and RNA, enabling high-quality NGS analysis.
Previous studies have relied on the number of gene mutations detected as a surrogate for NGS quality. A large study analyzed 7 genes in 500 samples obtained from biopsies and fine needle aspirations, and detected mutations in over 90% of samples. However, the quality of the samples, extracted DNA and sequencing itself are unknown. In addition, to our knowledge, no previous study has performed clinical targeted NGS using RNA extracted from FFPE samples.
The most comprehensive study to date has focused on the feasibility of EBUS-TBNA for NGS analysis. were sequence failures. Other biopsy methods were not analyzed, and RNA analysis was not performed.
We have shown that feasibility of CTNB, EBUS-TBNA and TBB are comparable to resection. We have found that 89% of all small biopsy samples gave adequate DNA quantity and quality, which resulted in an 86% success rate of NGS analysis. Of the 4 samples with low DNA yield and low average depth, 2 were samples from more than 2 years ago and 1 was a biopsy taken after chemotherapy was performed. Avoiding these samples should lead to a higher percentage of samples being suitable for NGS analysis.
In addition to NGS analysis using DNA, RNA analysis allows robust detection of fusion transcripts and exon skipping. 11 We have shown that small biopsy samples are feasible for targeted NGS analysis using RNA extracted from FFPE samples. RNA analysis was successfully performed in 30 of 37 biopsy samples. Of the 5 samples that failed, 4 had both low RNA yield and high RNA degradation, defined as RNA yield < 50 ng and DV200 < 50%. Of note, 3 out of 5 samples were biopsied by TBB only with the use of the guide sheath, and the same 3 samples also had low DNA yield of <100 ng. Using the guide sheath leads to higher cancer detection rate of TBB but smaller size of biopsied samples. 18 To perform NGS analysis from RNA, samples should be biopsied using standard forceps.
The Japanese Society of Pathology Guidelines recommend 10% neutral buffered formalin to fix samples intended for NGS analysis.
12
This is based on data showing higher DNA quality compared with 15% or 20% after 3 days. 12 The same figure shows that 10% and 20% neutral buffered formalin solution result in similar DNA yield after 1 day. Twenty percent allows faster fixation, and also results in higher RNA yield after 1 day compared with 10%. All our samples were fixed using 20% neutral buffered formalin and gave excellent results. Pathologists and researchers need to keep in mind that samples should be fixed for 24 hours or less.
Limitations of our study include the retrospective nature of our analysis and the small number of samples. More samples are needed before concluding that older archival tissue and post-chemotherapy tissue are better avoided. More samples are also necessary to determine whether DV200 is superior to RNA yield to predict successful RNA analysis.
In conclusion, CTNB, EBUS-TBNA and TBB mostly resulted in adequate DNA and RNA quality, enabling high-quality targeted NGS analysis. Our results indicate that small biopsies may be feasible for targeted NGS in general.
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